zygote,
the ideal is for the bone to rebuild forever because the bone breaks down forever. The balance between osteoclasts and osteoblasts is what keeps bones free of fissures and strong.

The speakers don't address the significance of CTX the bone marker for bone dissolution.

In the open mic session it was difficult to determine who was speaking, but several suggestions were made.
Run a prior P1NP for Forteo and again at three months
Run a prior P1NP for Tymlos and again at 1 month.
Run a prior P1NP for Rosozumab and again at 2 weeks if at all--not meaningful for treatment decision.
If the P1NP is below baseline Forteo you might double the Forteo (never heard that before)
If the P1NPs are below baseline at the end of the 18 months or two years, switch medications. Risidronate suggested.
There aren't studies so none of this is supported by more than the thinking of whoever is speaking. There was neither disagreement, nor agreement, but a caution to be careful about why we are doing the bone markers, and what prior treatment was given to the patient because prior treatment, say with bisphophonates, will delay response to anabolics in some cases up to six months. It is at 16:30 on the open mic.